CompletedNot Applicable

CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment

United States114 participantsStarted 2012-07-17

Plain-language summary

The investigators will collect samples of sputum from healthy volunteers and patients with cystic fibrosis for the purpose of: a) purifying airway mucins for plate-based binding studies and; b) assessment of the effects of carbohydrates on the rheologic properties of the sputum. This study has two hypotheses: 1. Lectins from Pseudomonas aeruginosa and Aspergillus fumigatus bind to airway mucins in a fucose-dependent manner, and this binding can be inhibited by fucosyl glycomimetic compounds. 2. Fucosyl glycomimetics will compete with Pseudomonas aeruginosa lectin (PA-IIL) and Aspergillus fumigatus lectin (AFL) and disrupt lectin-driven mucin cross-linking in CF sputum.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy control subjects: * Age 18-65 * No history of lung disease * Cystic fibrosis subjects: * Age 18-65 * No history of lung disease other than cystic fibrosis * Diagnosis of CF if sweat chloride values \> 60 mM on two separate pilocarpine iontophoresis sweat tests and/or two allelic CF-producing mutations in genetic analysis Exclusion Criteria: * Use of recreational drugs within 30 days prior to enrollment * Use of tobacco within 30 days prior to enrollment, or \> 10 pack-year tobacco history * Pregnant or lactating females

What they're measuring

Mucus viscosity

Timeframe: Up to one hour

Trial details

NCT IDNCT01533636

SponsorUniversity of California, San Francisco

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-03-01

View on ClinicalTrials.gov More Cystic Fibrosis trials